Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Optimization of preoperative chemotherapy for breast cancer using whole genome sequencing
jRCT1030250152Recruiting
- Start
- Dec 2023
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Open-label, single-arm trial of pembrolizumab in breast cancer, sponsored by none. Primary endpoint: Genomic and immunological factors correlating with pathological complete response (pCR). Started Dec 2023; status: recruiting.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on jRCT1030250152.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1030250152.